• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Bio-Rad Laboratories

Bio-Rad Laboratories

  1. Global POC HbA1C Testing Market 2017-2021 with Abbott, Alere & Bio-Rad Laboratories Dominating - Research and Markets

    Global POC HbA1C Testing Market 2017-2021 with Abbott, Alere & Bio-Rad Laboratories Dominating - Research and Markets

  2. Bio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017

    Bio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017

  3. Real-time PCR (qPCR) and Digital PCR (dPCR) Market 2017: Key Players are Thermo Fisher, Bio-Rad Labs, Qiagen, Abbott & Cepheid - Research and Markets

    Real-time PCR (qPCR) and Digital PCR (dPCR) Market 2017: Key Players are Thermo Fisher, Bio-Rad Labs, Qiagen, Abbott & Cepheid - Research and Markets

  4. Liquid Biopsy Market by Product & Services, Biomarker and Technology, Cancer Type, End Users & Geography - Research and Markets

    Liquid Biopsy Market by Product & Services, Biomarker and Technology, Cancer Type, End Users & Geography - Research and Markets

  5. Label-Free Detection Market - Drug Discovery Programs in the Americas to Boost Sales | Technavio

    Label-Free Detection Market - Drug Discovery Programs in the Americas to Boost Sales | Technavio

  6. Global Point-of-Care Testing Market Analysis 2017-2024 - Companies Profiles, Size, Share, Growth, Trends - Research and Markets

    Global Point-of-Care Testing Market Analysis 2017-2024 - Companies Profiles, Size, Share, Growth, Trends - Research and Markets

  7. Novacyt: Proposed Admission to Trading on AIM and Successful Conditional Capital Raise of €9.7 Million

    Novacyt: Proposed Admission to Trading on AIM and Successful Conditional Capital Raise of €9.7 Million

  8. Genomics Market by Product and Services, Technology, Process & Application - Forecast to 2022 - Research and Markets

    Genomics Market by Product and Services, Technology, Process & Application - Forecast to 2022 - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.